365 related articles for article (PubMed ID: 24301242)
1. Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis.
Kircik L; Lebwohl MG; Del Rosso JQ; Bagel J; Stein Gold L; Weiss JS
J Drugs Dermatol; 2013 Dec; 12(12):1404-10. PubMed ID: 24301242
[TBL] [Abstract][Full Text] [Related]
2. Desoximetasone 0.25% Spray for the Relief of Scaling in Adults With Plaque Psoriasis.
Keegan BR
J Drugs Dermatol; 2015 Aug; 14(8):835-40. PubMed ID: 26267727
[TBL] [Abstract][Full Text] [Related]
3. Topical 0.25% desoximetasone spray efficacy for moderate to severe plaque psoriasis: a randomized clinical trial.
Saleem MD; Negus D; Feldman SR
J Dermatolog Treat; 2018 Feb; 29(1):32-35. PubMed ID: 28504031
[TBL] [Abstract][Full Text] [Related]
4. Desoximetasone 0.25% spray, adrenal suppression and efficacy in extensive plaque psoriasis.
Saleem MD; Feldman SR
J Dermatolog Treat; 2018 Feb; 29(1):36-38. PubMed ID: 28494626
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis.
Jarratt MT; Clark SD; Savin RC; Swinyer LJ; Safley CF; Brodell RT; Yu K
Cutis; 2006 Nov; 78(5):348-54. PubMed ID: 17186795
[TBL] [Abstract][Full Text] [Related]
9. Is topical treatment effective for psoriasis in patients who failed topical treatment?
Okwundu N; Cardwell L; Cline A; Richardson I; Feldman SR
J Dermatolog Treat; 2021 Feb; 32(1):41-44. PubMed ID: 31132897
[No Abstract] [Full Text] [Related]
10. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
11. Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.
Menter MA; Caveney SW; Gottschalk RW
J Drugs Dermatol; 2012 Nov; 11(11):1348-54. PubMed ID: 23135087
[TBL] [Abstract][Full Text] [Related]
12. DFD-01, a Novel Medium Potency Betamethasone Dipropionate 0.05% Emollient Spray, Demonstrates Similar Efficacy to Augmented Betamethasone Dipropionate 0.05% Lotion for the Treatment of Moderate Plaque Psoriasis.
Fowler JF; Hebert AA; Sugarman J
J Drugs Dermatol; 2016 Feb; 15(2):154-62. PubMed ID: 26885782
[TBL] [Abstract][Full Text] [Related]
13. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis.
Beutner K; Chakrabarty A; Lemke S; Yu K
J Drugs Dermatol; 2006 Apr; 5(4):357-60. PubMed ID: 16673804
[TBL] [Abstract][Full Text] [Related]
14. Improvement in Extensive Moderate Plaque Psoriasis With a Novel Emollient Spray Formulation of Betamethasone Dipropionate 0.05.
Stein Gold L; Jackson JM; Knuckles ML; Weiss JS
J Drugs Dermatol; 2016 Mar; 15(3):334-42. PubMed ID: 26954319
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the Betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: a randomized, parallel-group, active-controlled, phase III study.
Naldi L; Yawalkar N; Kaszuba A; Ortonne JP; Morelli P; Rovati S; Mautone G
Am J Clin Dermatol; 2011 Jun; 12(3):191-201. PubMed ID: 21284407
[TBL] [Abstract][Full Text] [Related]
16. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis.
Zhu X; Wang B; Zhao G; Gu J; Chen Z; Briantais P; Andres P
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):466-72. PubMed ID: 17373972
[TBL] [Abstract][Full Text] [Related]
17. Topical Desoximetasone 0.25% Spray and Its Vehicle Have Little Potential for Irritation or Sensitization.
Nadkarni A; Saleem MD; Feldman SR
J Drugs Dermatol; 2017 Aug; 16(8):755-758. PubMed ID: 28809990
[TBL] [Abstract][Full Text] [Related]
18. Predicting improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray.
Feldman SR; Winkelman W; Baum E; Preston N
J Drugs Dermatol; 2013 Dec; 12(12):1456-60. PubMed ID: 24301248
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.
Feldman SR; Mills M; Brundage T; Eastman WJ
J Drugs Dermatol; 2013 Mar; 12(3):300-6. PubMed ID: 23545912
[TBL] [Abstract][Full Text] [Related]
20. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.
Pariser D; Bukhalo M; Guenthner S; Kempers S; Shideler S; Gold LS; Tschen E; Berg J; Ferdon MB; Dromgoole S
J Drugs Dermatol; 2017 Mar; 16(3):234-240. PubMed ID: 28301619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
